» Articles » PMID: 8792035

Migraine Without Aura and Migraine with Aura Are Distinct Clinical Entities: a Study of Four Hundred and Eighty-four Male and Female Migraineurs from the General Population

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 1996 Jun 1
PMID 8792035
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical characteristics of migraine without aura (MO) and migraine with aura (MA) were compared in 484 migraineurs from the general population. We used the criteria of the International Headache Society. The lifetime prevalence of MO was 14.7% with a M:F ratio of 1:2.2; that of MA was 7.9% with a M:F ratio of 1:1.5. The female preponderance was significant in both MO and MA. The female preponderance was present in all age groups in MA, but was first apparent after menarche in MO, suggesting that female hormones are an initiating factor in MO, but not likely so in MA. The age at onset of MO followed a normal distribution, whereas the age at onset of MA was bimodally distributed, which could be explained by a composition of two normal distributions. The estimated separation between the two groups of MA was at age 26 years among the females and age 31 years among the males. The observed number of persons with co-occurrence of MO and MA was not significantly different from the expected number. The specificity and importance of premonitory symptoms are questioned, but prospective studies are needed. Bright light was a precipitating factor in MA, but not in MO. Menstruation was a precipitating factor in MO, but not likely in MA. Both MO and MA improved during pregnancy. The clinical differences indicate that MO and MA are distinct entities.

Citing Articles

Migraine in men.

Fitzek M, Boucherie D, de Vries T, Handtmann C, Fathi H, Raffaelli B J Headache Pain. 2025; 26(1):3.

PMID: 39754046 PMC: 11697684. DOI: 10.1186/s10194-024-01936-7.


Association between internet use and primary headache severity among Hungarian university students: a cross-sectional study.

Radvanyi I, Tibold A, Fejes E, Mak K, Beke S, Feher G Front Public Health. 2024; 12:1445856.

PMID: 39737465 PMC: 11683049. DOI: 10.3389/fpubh.2024.1445856.


I'm Getting a Migraine: A Comparative Evaluation of Patient and Clinician Interpretations of Migraine Symptoms.

Fischer J, Tolisano A, Navarro A, Abuzeid W, Humphreys I, Akbar N Ochsner J. 2024; 24(4):262-272.

PMID: 39720823 PMC: 11666111. DOI: 10.31486/toj.24.0071.


Sumatriptan-naproxen sodium in migraine: A review.

Wilcha R, Afridi S, Barbanti P, Diener H, Patrick Jurgens T, Lanteri-Minet M Eur J Neurol. 2024; 31 Suppl 2:e16434.

PMID: 39318200 PMC: 11422667. DOI: 10.1111/ene.16434.


Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study.

Jantzen F, Chaudhry B, Younis S, Norgaard I, Cullum C, Do T Sci Rep. 2024; 14(1):18068.

PMID: 39103416 PMC: 11300825. DOI: 10.1038/s41598-024-68915-5.